Form 4: STAAR Surgical Director Lilian Zhou Granted Equity Options as Part of Compensation Program

STAAR Surgical Co. Director Lilian Yansheng Zhou was granted 19,415 stock options as part of the company's annual non-employee director equity compensation program.

Summary

• Lilian Yansheng Zhou, a Director of STAAR Surgical Co. (STAA), acquired 19,415 common stock options.
• The options were granted on June 18, 2025, with an exercise price of $16.85 per share.
• This grant is part of the Corporation's annual non-employee director equity compensation program for the 2025-2026 term.
• The equity awards are set to vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.
• The options have an expiration date of June 17, 2035.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is a routine compensation event and generally viewed as positive for aligning interests, but it does not contain new financial performance data or strategic announcements that would significantly alter sentiment.

Positives

• The grant of equity awards to a non-employee director aligns the director's interests with those of shareholders, incentivizing long-term company performance and value creation.
• This is a standard practice for attracting and retaining qualified board members.

Future Outlook

The equity awards are set to vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders, indicating a future milestone for the director's compensation and continued alignment of interests.

Management Comments

• The equity awards were granted "pursuant to the Corporation's annual non-employee director equity compensation program for the 2025-2026 term."

Industry Context

The granting of stock options to non-employee directors is a common and widely accepted practice across various industries, including the medical device sector where STAAR Surgical operates. This method of compensation is used to attract and retain experienced board members while aligning their long-term financial interests with the company's performance and shareholder value.

Corporate Governance

Related Party Transactions

• Grant of 19,415 common stock options to Lilian Yansheng Zhou, a Director of STAAR Surgical Co., as part of the company's annual non-employee director equity compensation program.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with long-term shareholder value, potentially leading to more focused governance and strategic decisions that benefit shareholders.

Next Steps

• The granted equity awards will vest in full on the earlier of June 18, 2026, or the Corporation's 2026 Annual Meeting of Shareholders.

Key Dates

Keywords

STAAR Surgical, STAA, Form 4, Insider Transaction, Stock Options, Equity Compensation, Director Compensation, Lilian Zhou